Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2024

Genmab — Juli 2024

Planlagt Fastgjort Låst Flyttet Genmab
568 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    JKY_VH
    wrote on sidst redigeret af
    #128

    Ja, det er der jo et vist potentiale i 😄

    1 Reply Last reply
    0
    • P Offline
      P Offline
      peter12
      wrote on sidst redigeret af
      #129

      Er der nogen der ved om Genmab evt kan forny deres CD38 patent https://patents.google.com/patent/JP2024075737A/en

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #130

        Det er på HexCD38

        1 Reply Last reply
        0
        • P Offline
          P Offline
          peter12
          wrote on sidst redigeret af
          #131

          Ok det kan være lidt svært at se 😉

          1 Reply Last reply
          0
          • T Offline
            T Offline
            transalp
            wrote on sidst redigeret af
            #132

            Go morgen.. 🙂

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #133

              Godmorgen 🙂

              1 Reply Last reply
              0
              • L Offline
                L Offline
                LP90
                wrote on sidst redigeret af
                #134

                Godmorgen 🙂

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bibob
                  wrote on sidst redigeret af
                  #135

                  God morgen. 🙂

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    lahn1
                    wrote on sidst redigeret af
                    #136

                    Godmorgen 🙂

                    1 Reply Last reply
                    0
                    • V Offline
                      V Offline
                      Vitus
                      wrote on sidst redigeret af
                      #137

                      StockBull….har du ikke kludder i
                      månedernes rækkefølge….

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #138

                        Ben Derman
                        @bdermanmd
                        Let’s talk about freedom…from spending as much time in clinic!

                        We piloted discontinuation of premeds for daratumumab starting cycle 2 (we kept dex) and had no adverse events! https://x.com/bdermanmd/status/1808701446549807569

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #139

                          We shortened each visit by 1 hour (= $740) amounting to 194 hours and $140K saved in just 6 months.

                          At scale, this has huge potential implications - $21,900 saved per patient adhering to ANDROMEDA and $27K per patient per GRIFFIN (similar for PERSEUS)!

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #140

                            The New England Journal of Medicine - Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2313811

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #141

                              Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed https://finance.yahoo.com/news/health-canada-authorizes-rybrevant-amivantamab-120000634.html

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #142

                                PERSEUS Data Support Daratumumab as New Standard of Care for Myeloma https://bloodcancerstoday.com/post/perseus-data-support-daratumumab-as-new-standard-of-care-for-myeloma

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  lahn1
                                  wrote on sidst redigeret af
                                  #143

                                  Iflg Bloomberg overgåes væksten i Gmab de næste 5 år (17,5%) kun af LLY. NVO (17,2%) blandt alle de 15 største pharma/biotech. En vækst historie som markedet tilsyneladende ikke tror på, da den skal drives af Gen1046 og Epco. HexaCD38 fylder ingenting de næste 5år.

                                  1 Reply Last reply
                                  0
                                  • L Offline
                                    L Offline
                                    lahn1
                                    wrote on sidst redigeret af
                                    #144

                                    Uden de store armbevægelser er 2024 det sidste år DARA står for størstedelen af væksten. Herefter er det de NYE produkter der skaber vækst.

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #145

                                      LLYs aktiekursudvikling er helt vild og prissætningen ditto.

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #146

                                        Forventninger til C25 halvårsregnskaber https://proinvestor.com/boards/121235

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #147

                                          LLY fra X https://x.com/financelancelot/status/1808207982452208060?s=61&t=JauvgjicW74kU8sNN3xEFA

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper